107 related articles for article (PubMed ID: 7913236)
1. Latency increase of auditory-evoked potential component N1 predicts poor neuroleptic response in schizophrenic patients.
Adler G; Markert U; Gattaz WF
Pharmacopsychiatry; 1994 Mar; 27(2):68-9. PubMed ID: 7913236
[TBL] [Abstract][Full Text] [Related]
2. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
Stefánsson SB; Jónsdóttir TJ
Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
[TBL] [Abstract][Full Text] [Related]
3. Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
Schlör KH; Moises HW; Haas S; Rieger H
Pharmacopsychiatry; 1985 Sep; 18(5):293-6. PubMed ID: 4048264
[TBL] [Abstract][Full Text] [Related]
4. Relationship between residual symptomatology and auditory evoked potentials in schizophrenic outpatients.
Hegerl U; Gaebel W; Ulrich G
Pharmacopsychiatry; 1988 Nov; 21(6):329-30. PubMed ID: 2907638
[No Abstract] [Full Text] [Related]
5. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
Asato N; Hirayasu Y; Hiramatsu K; Ohta H
Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
[TBL] [Abstract][Full Text] [Related]
6. Auditory evoked potentials in schizophrenic patients before and during neuroleptic treatment. Relationship to psychopathological state.
Adler G; Gattaz WF
Eur Arch Psychiatry Clin Neurosci; 1993; 242(6):357-61. PubMed ID: 8323986
[TBL] [Abstract][Full Text] [Related]
7. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
Kathmann N; Wagner M; Rendtorff N; Engel RR
Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
[No Abstract] [Full Text] [Related]
8. Clinical response to sleep deprivation and auditory-evoked potentials--preliminary results.
Danos P; Kasper S; Scholl HP; Kaiser J; Ruhrmann S; Höflich G; Möller HJ
Pharmacopsychiatry; 1994 Mar; 27(2):70-1. PubMed ID: 8029315
[TBL] [Abstract][Full Text] [Related]
9. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment.
Hirayasu Y; Asato N; Ohta H; Hokama H; Arakaki H; Ogura C
Biol Psychiatry; 1998 Feb; 43(4):244-53. PubMed ID: 9513733
[TBL] [Abstract][Full Text] [Related]
10. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
Nagase Y; Okubo Y; Toru M
Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
Moxon KA; Gerhardt GA; Adler LE
Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
[TBL] [Abstract][Full Text] [Related]
12. Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia.
Wang J; Hirayasu Y; Hokama H; Tanaka S; Kondo T; Zhang M; Xiao Z
Psychiatry Clin Neurosci; 2005 Apr; 59(2):209-14. PubMed ID: 15823170
[TBL] [Abstract][Full Text] [Related]
13. [Negative schizophrenic symptomatology and the P 300 potential].
Drouet A; Hort-Legrand C; Féline A; Métral S
Encephale; 1993; 19(3):229-35. PubMed ID: 8275908
[TBL] [Abstract][Full Text] [Related]
14. Reduced auditory evoked potential component N100 in schizophrenia--a critical review.
Rosburg T; Boutros NN; Ford JM
Psychiatry Res; 2008 Dec; 161(3):259-74. PubMed ID: 18926573
[TBL] [Abstract][Full Text] [Related]
15. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
[TBL] [Abstract][Full Text] [Related]
16. [The P 300 potential in schizophrenia].
Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
[TBL] [Abstract][Full Text] [Related]
17. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Lombertie ER; Durelle G; Fuseau A
Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
[TBL] [Abstract][Full Text] [Related]
18. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients.
Freedman R; Adler LE; Waldo MC; Pachtman E; Franks RD
Biol Psychiatry; 1983 May; 18(5):537-51. PubMed ID: 6134559
[TBL] [Abstract][Full Text] [Related]
19. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.
Nedopil N; Pflieger R; Rüther E
Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576
[TBL] [Abstract][Full Text] [Related]
20. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
